GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody

GENEVA--(BUSINESS WIRE)-- GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19 (post-COVID), announced today the joint publications in the leading scientific journal “Annals of Neurology” of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS). NINDS is part of the National Institutes of Health (NIH) of the United States. The two publications describe the novel pathogenic mechanism of HERV-K in sporadic ALS and confirm the rationale for the therapeutic relevance of GeNeuro’s antibody to neutralize this neurotoxic protein.

Annals of Neurology is an official journal of the American Neurological Association. The online publications and their hard copy version in the last issue of the journal (HERV-K envelope in spinal fluid of Amyotrophic Lateral Sclerosis is toxic - Steiner et al, & Antibody response to HML-2 may be protective in Amyotrophic Lateral Sclerosis - Garcia-Montojo et al. - Annals of Neurology) present preclinical data showing that HERV-K/HML-2 Envelope protein (HERV-K ENV) is present in the cerebrospinal fluid (CSF) of sporadic ALS patients, leads to neuronal cell injury and death, and targets a now identified cellular receptor. The studies also show that the neurotoxic properties of the HERV-K ENV protein from ALS patients’ CSF are neutralized by GeNeuro’s anti-HERV-K ENV antibody and that, in patients with sporadic ALS, higher levels of autoantibodies targeting the HERV-K ENV protein are associated with a longer survival.

Click here to read the full press release

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It owns rights to 17 patent families protecting its technology.

For more information, visit: www.geneuro.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005784/en/